Stay up to date and read the latest news about Wellington Partners and the Wellington Partners portfolio.

Filter Categories
Show all
Portfolio News
Wellington Partners
  • 19. May 2022
    TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Canada
  • 18. May 2022
    Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
  • 12. May 2022
    Koa Health Partners with Virgin Pulse to Extend Mental Health Programs via VP+ Program
  • 11. May 2022
    Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
  • 10. May 2022
    UroMems Appoints Steffen Hovard to Chairman of the Board of Directors
  • 9. May 2022
    Digital Therapeutics Leader Sidekick Raises $55M Series B To Drive Further Growth
  • 25. April 2022
    TRiCares Announces Successful First in Human Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Germany
  • 19. April 2022
    eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer
  • 13. April 2022
    ONWARD Announces Additions to Leadership Team
  • 11. April 2022
    PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients
  • 7. April 2022
    ONWARD Medical’s Parkinson’s Therapy Published in New England Journal of Medicine
  • 4. April 2022
    eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer
  • 28. March 2022
    ONWARD adds new brain-spine interface and Parkinson’s disease IP to license agreements
  • 15. March 2022
    Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO
  • 9. March 2022
    First participants enrolled in ONWARD’s LIFT home study
  • 7. February 2022
    ONWARD medical’s technology enables walking and standing after severe spinal cord injuries
  • 12. January 2022
    Moderna and Carisma establish collaboration to develop in vivo engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
  • 10. January 2022
    Creative Balloons appoints David Johnson as Chairman of the Board of Directors
  • 16. December 2021
    ONWARD Announces Completion of Enrollment in the Up- LIFT Pivotal Trial of ARC Therapy for Spinal Cord Injury
  • 14. December 2021
    Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
  • 7. December 2021
    ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Gamma-delta T Cells in Science Translational Medicine
  • 7. December 2021
    Confo Therapeutics Enters Collaborative Agreement With Regeneron
  • 6. October 2021
    iOmx Therapeutics raises EUR 65 million in Series B round
  • 17. September 2021
    ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
  • 26. August 2021
    TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart ...
  • 23. June 2021
    Quanta Raises $245 Million to Accelerate Commercialization of its SC+ Portable Hemodialysis System
  • 9. April 2021
    Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
  • 6. April 2021
    UroMems Completes €23 Million Series B Financing
  • 18. March 2021
    Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
  • 4. March 2021
    Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
  • 2. March 2021
    eGenesis Announces $125 Million Series C Financing
  • 24. February 2021
    Creative Balloons closes €15 million growth financing and appoints Frank Gehres as CEO
  • 29. January 2021
    ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury
  • 12. January 2021
    ONWARD Announces First Patient Enrolled in the Up-LIFT Pivotal Trial Assessing Safety and Effectiveness of ARC Therapy for Spinal Cord Injury
  • 12. January 2021
    ONWARD Completes $32 Million Financing Round
  • 8. January 2021
    Quanta Receives FDA 510(k) Clearance for the SC+ Hemodialysis System Setting the Stage for US Market Launch
  • 8. January 2021
    PerkinElmer to Acquire Oxford Immunotec Global PLC
  • 8. January 2021
    CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies
  • 8. January 2021
    CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer
  • 15. December 2020
    MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials
  • 15. December 2020
    Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO
  • 11. November 2020
    Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
  • 5. November 2020
    Koa Health secures over €14m initial funding and spins out of Telefónica’s moonshot factory
  • 28. October 2020
    Digital therapeutics leader Sidekick raises $20M in Series A funding round led by Wellington and Asabys
  • 27. July 2020
    CARISMA Therapeutics announces FDA clearance of IND application for first-ever engineered macrophage immunotherapy
  • 2. July 2020
    Immatics announces completion of business combination and listing on NASDAQ
  • 1. July 2020
    SIRS Therapeutics: F4 Pharma’s FX06 shows promising results in critically ill COVID-19 patients
  • 10. June 2020
    Confo Therapeutics expands board with appointment of Rob Scott as Independent Director
  • 9. June 2020
    GTX Medical was granted FDA Breakthrough Device Designation for Go-2 Targeted Epidural Spinal Stimulation (TESS) system
  • 4. June 2020
    Confo Therapeutics appoints Paolo Vicini as Chief Development Officer
  • 26. May 2020
    Wellington Partners’s portfolio company Themis to be acquired by MSD
  • 14. May 2020
    Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France
  • 27. April 2020
    UroMems appoints medical device industry leader Steffen Hovard to Board of Directors
  • 20. April 2020
    GTX Medical appoints John Murphy as Chief Technology Officer
  • 17. April 2020
    Themis announces Iain Dukes to join the company’s supervisory board
  • 16. April 2020
    STipe Therapeutics appoints Dr Natalie Sacks as Independent Board Member and Dr Richard Bethell as Chief Development Officer
  • 15. April 2020
    Wellington invests in SIRS Therapeutics to develop FX06 for treatment of ARDS in COVID-19 patients in collaboration with F4 Pharma
  • 26. March 2020
    First patient dosed in EVICTION trial evaluating ImCheck’s lead anti-cancer drug ICT01
  • 24. March 2020
    Carisma Therapeutics: First-of-its-kind engineered macrophage cell therapy platform shows ability to reduce tumor burden & activate anti-tumor immunity, improving overall survival in pre-clinical cancer models
  • 8. January 2020
    Karl Naegler joins Wellington Partners as Managing Partner
  • 4. December 2019
    Wellington Partners participates in $53 Million Series B financing at ImCheck
  • 7. November 2019
    Wellington Partners participates in $100 Million Series B financing at eGenesis
  • 25. October 2019
    UroMems wins prestigious Prix Galien Med’Start-Up for best collaboration in the medtech or digital sector
  • 22. October 2019
    GTX medical & NeuroRecovery Technologies merge to create leading neurostimulation company for SCI
  • 1. October 2019
    Themis and ZIKAVAX consortium announce initiation of Phase 1 Zika vaccine trial
  • 30. September 2019
    STipe Therapeutics launches with EUR 20 million Series A financing
  • 30. September 2019
    iOmx Therapeutics announces discovery of novel, druggable immune-checkpoint targets
  • 30. September 2019
    AMBOSS raises €30M in Series B
  • 26. September 2019
    Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock
  • 23. September 2019
    FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019
  • 18. September 2019
    Themis raises EUR 40 Million in Series D financing round backed by US/EU consortium
  • 29. August 2019
    Adrenomed Supervisory Board appoints Jens Schneider-Mergener as CEO & Jens Zimmermann (CMO) joins the Executive Board
  • 28. August 2019
    Immatics and Celgene enter strategic collaboration to develop novel adoptive cell therapies
  • 22. August 2019
    Themis announces exclusive license and research collaboration agreement with MSD to develop vaccine candidates
  • 31. July 2019
    Wellington Partners raises EUR 210 million life science fund
  • 29. July 2019
    Quanta raises $48 million in Series C funding round
  • 8. July 2019
    Immatics appoints Harpreet Singh as Chief Executive Officer
  • 21. June 2019
    Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication
  • 4. June 2019
    CEPI awards up to US$21 million to Themis for Phase 3 Chikungunya Vaccine Development
  • 28. May 2019
    US patent grants strengthen SNIPR BIOME’s approach to enhance immuno-oncology outcomes by microbiome modulation
  • 7. May 2019
    Wellington Partners co-leads €30 million Series A financing in Confo Therapeutics
  • 11. March 2019
    SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials
  • 27. February 2019
    Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
  • 27. February 2019
    Themis receives FDA fast track designation for Chikungunya vaccine candidate
  • 7. January 2019
    AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies
  • 26. November 2018
    Adrenomed closes €24 million financing led by Wellington Partners and HBM
  • 6. November 2018
    Themis publishes compelling Phase 2 results for lead vaccine candidate against Chikungunya fever in "The Lancet"
  • 11. October 2018
    Themis announces exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies
  • 9. October 2018
    Sphingotec raises €20 million from HBM and Wellington Partners
  • 6. September 2018
    Themis presents Phase II interim results for Chikungunya vaccine candidate at ASTMH 2017
  • 27. June 2018
    Carisma Therapeutics announces $53 million Series A financing
  • 4. June 2018
    TRiCares closes €22 million Series B financing round
  • 27. March 2018
    4SC: Yakult Honsha joins pivotal RESMAIN study of resminostat in CTCL
  • 6. March 2018
    CEPI partners with Themis to advance vaccines against Lassa fever and MERS
  • 26. February 2018
    Themis establishes Scientific Advisory Board of experts in virology and vaccine development
  • 1. February 2018
    Physicians at Helios gain access to Amboss platform
  • 17. January 2018
    Immatics appoints Thomas Ulmer as Chief Financial Officer
  • 4. January 2018
    Themis raises EUR 10 million in Series C financing to advance clinical pipeline
  • 25. October 2017
    Ambu acquires Wellington Partners portfolio company invendo medical
  • 4. October 2017
    Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies
  • 28. September 2017
    Immatics initiates first Phase I clinical trial of ACTengine® approach in patients with advanced solid cancers
  • 8. September 2017
    Wellington featured in BioCentury
  • 6. September 2017
    MSD to acquire Rigontec
  • 5. September 2017
    Themis: Chikungunya vaccine development towards Phase III trials receives £ 3 Mio. boost by Innovate UK
  • 21. August 2017
    Immatics initiates personalized adoptive cellular therapy in patients with relapsed and/or refractory solid cancers using its pioneering target warehouse
  • 27. July 2017
    Themis starts Phase II clinical study of Chikungunya vaccine in endemic area
  • 6. July 2017
    4SC secures EUR 41 million from successful capital increase
  • 8. June 2017
    Themis starts Phase II trial of Chikungunya vaccine in the U.S.
  • 3. May 2017
    Rigontec starts FIH Phase I/II trial of RIG-I agonist RGT100 & appoints new CMO
  • 7. December 2016
    AYOXXA appoints permanent CEO
  • 5. December 2016
    invendo medical announces CE mark
  • 17. November 2016
    Chiesi Group acquires Atopix
  • 15. November 2016
    Wellington invests in Uromems
  • 14. November 2016
    Rigontec appoints new CSO
  • 7. November 2016
    Ayoxxa announces new CEO
  • 7. November 2016
    Immatics and Amgen sign $1B deal
  • 5. October 2016
    4SC: overall survival benefit for resminostat in first-line liver cancer study subgroup
  • 5. October 2016
    4SC's Resminostat shows survival benefit
  • 22. September 2016
    Wellington invests in iOmx €40m Series A
  • 13. September 2016
    Themis Zika Vaccine Developement receives 1 Mio GBP Boost
  • 13. September 2016
    Themis vector technology featured in quest for Zika vaccine by Top EU-groups
  • 13. September 2016
    Themis launches Zika vaccine clinical trial
  • 6. September 2016
    Rigontec extends Series A with additional €15 million
  • 16. June 2016
    Resminostat boosts cancer immunotherapy
  • 7. June 2016
    NEUWAY Awarded €2.95M Grant
  • 12. May 2016
    Invendo receives FDA clearance for Invendoscopy E200 System
  • 12. May 2016
    Themis announces exclusive license with Institut Pasteur and Zika vaccine
  • 12. May 2016
    Symetis acquires Middle Peak Medical
  • 12. May 2016
    Boston Scientific acquires Symetis for USD 435m in cash